Compare CHEF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | IDYA |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2011 | 2019 |
| Metric | CHEF | IDYA |
|---|---|---|
| Price | $69.50 | $32.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $76.83 | $51.21 |
| AVG Volume (30 Days) | 327.9K | ★ 789.8K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 61.90 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $1,301,520,000.00 | $218,710,000.00 |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $7.48 | $97.58 |
| P/E Ratio | $58.76 | ★ N/A |
| Revenue Growth | 9.11 | ★ 3024.43 |
| 52 Week Low | $45.00 | $13.45 |
| 52 Week High | $71.04 | $39.28 |
| Indicator | CHEF | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 46.01 |
| Support Level | $60.64 | $29.47 |
| Resistance Level | $71.04 | $33.03 |
| Average True Range (ATR) | 2.36 | 1.60 |
| MACD | 0.43 | -0.02 |
| Stochastic Oscillator | 83.98 | 52.23 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.